Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares (KNSA) Stock
NASDAQ · KNSA
75.04
Fundamentals
Market cap
$5.86B
Price / Earnings ratio
72.9x
Price / Sales ratio
7.0x
Price / Book ratio
9.0x
Return on assets
10.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

Zacks Investment Research
Kiniksa Pharmaceuticals Stock Rallies 41% in Three Months: Here's Why
NeutralKNSASeptember 17, 2026
Zacks Investment ResearchNeutral
Kiniksa Pharmaceuticals Stock Rallies 41% in Three Months: Here's Why
KNSA

MarketBeat
Kiniksa Highlights ARCALYST Growth as KPL-387 Advances Into Phase 3
NeutralKNSAAugust 15, 2026
MarketBeatNeutral
Kiniksa Highlights ARCALYST Growth as KPL-387 Advances Into Phase 3
KNSA

Zacks Investment Research
KNSA Q2 Earnings Call Backs Higher ARCALYST Sales Outlook
NeutralKNSAAugust 3, 2026
Zacks Investment ResearchNeutral
KNSA Q2 Earnings Call Backs Higher ARCALYST Sales Outlook
KNSA

Zacks Investment Research
Earnings Estimates Rising for Kiniksa Pharmaceuticals International, plc (KNSA): Will It Gain?
NeutralKNSAJuly 30, 2026
Zacks Investment ResearchNeutral
Earnings Estimates Rising for Kiniksa Pharmaceuticals International, plc (KNSA): Will It Gain?
KNSA
Technicals
OscillatorsSell5 Indicators
Moving AveragesSell12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral0
Buy6
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2025
813M537M268M0
Debt & Balance Sheet
Total assets
Total liabilities
2025
916M605M302M0
Revenue to Profit
2025$677.6M
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$59.0M
Net incomeEarnings
No data available
% positive news of 10 articles
published over the past 14 days
Latest news

Zacks Investment Research
Kiniksa Pharmaceuticals Stock Rallies 41% in Three Months: Here's Why
NeutralKNSASeptember 17, 2026
Zacks Investment ResearchNeutral
Kiniksa Pharmaceuticals Stock Rallies 41% in Three Months: Here's Why
KNSA

MarketBeat
Kiniksa Highlights ARCALYST Growth as KPL-387 Advances Into Phase 3
NeutralKNSAAugust 15, 2026
MarketBeatNeutral
Kiniksa Highlights ARCALYST Growth as KPL-387 Advances Into Phase 3
KNSA

Zacks Investment Research
KNSA Q2 Earnings Call Backs Higher ARCALYST Sales Outlook
NeutralKNSAAugust 3, 2026
Zacks Investment ResearchNeutral
KNSA Q2 Earnings Call Backs Higher ARCALYST Sales Outlook
KNSA

Zacks Investment Research
Earnings Estimates Rising for Kiniksa Pharmaceuticals International, plc (KNSA): Will It Gain?
NeutralKNSAJuly 30, 2026
Zacks Investment ResearchNeutral
Earnings Estimates Rising for Kiniksa Pharmaceuticals International, plc (KNSA): Will It Gain?
KNSA

MarketBeat
Kiniksa Pharmaceuticals International Q2 Earnings Call Highlights
NeutralKNSAJuly 28, 2026
MarketBeatNeutral
Kiniksa Pharmaceuticals International Q2 Earnings Call Highlights
KNSA

Zacks Investment Research
Kiniksa Pharmaceuticals International, plc (KNSA) Q2 Earnings Match Estimates
NeutralKNSAJuly 28, 2026
Zacks Investment ResearchNeutral
Kiniksa Pharmaceuticals International, plc (KNSA) Q2 Earnings Match Estimates
KNSA

Zacks Investment Research
5 Stocks With Recent Price Strength Despite Recent Market Volatility
NeutralKNSAJuly 23, 2026
Zacks Investment ResearchNeutral
5 Stocks With Recent Price Strength Despite Recent Market Volatility
KNSA

Zacks Investment Research
Recent Price Trend in Kiniksa Pharmaceuticals International, plc (KNSA) is Your Friend, Here's Why
NeutralKNSAJuly 22, 2026
Zacks Investment ResearchNeutral
Recent Price Trend in Kiniksa Pharmaceuticals International, plc (KNSA) is Your Friend, Here's Why
KNSA

Zacks Investment Research
4 Top-Ranked Stocks With Solid Net Profit Margins to Boost Your Gains
NeutralKNSAJuly 14, 2026
Zacks Investment ResearchNeutral
4 Top-Ranked Stocks With Solid Net Profit Margins to Boost Your Gains
KNSA

Zacks Investment Research
Kiniksa Pharmaceuticals International, plc (KNSA) Is a Great Choice for 'Trend' Investors, Here's Why
NeutralKNSAJuly 6, 2026
Zacks Investment ResearchNeutral
Kiniksa Pharmaceuticals International, plc (KNSA) Is a Great Choice for 'Trend' Investors, Here's Why
KNSA
About Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
SectorHealthcare
IndustryBiotechnology
Employees366
CEOMr. Sanjiv K. Patel
IPO DateMay 24, 2018
HeadquartersLondon, United Kingdom
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Sanjiv K. Patel | CEO & Chairman of the Board | 1969 |
| Mr. Mark A. Ragosa C.F.A. | Executive VP & CFO | 1974 |
| Mr. Ross Michael Moat | Executive VP, COO & Principal Operating Officer | 1980 |
| Dr. John F. Paolini FACC, M.D., Ph.D. | Executive VP & Chief Medical Officer | 1965 |
| Mr. Eben Tessari | Consultant | 1982 |
| Mr. Michael R. Megna CPA | Senior VP & Chief Accounting Officer | 1971 |
| Ms. Mei Jang | Senior VP & Chief Technical Officer | — |
| Mr. Jonathan Kirshenbaum | Investor Relations Officer | — |
| Mr. Douglas J. Barry | Senior VP, Chief Legal Officer & Secretary | — |
| Ms. Martina Struck Ph.D. | Senior VP & Chief Regulatory Officer | — |
Fundamentals
Valuation
Market cap$5.86B
Price-to-sales ratio6.99
Price-to-book value8.99
Price-earnings ratio72.90
Return on Equity13.00%
Return on Sales14.00%
Return on Assets10.00%
PEG ratioN/A
Earnings Per Share
Earnings Per Share$1.07
Income Statement
Average volume526,139
EBITDA$111.49M
1 year high (52w)$82.94
1 year low (52w)$35.20
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsSell5 Indicators
Moving AveragesSell12 Indicators
What the experts say
6 Wall Street Analyst Ratings
BUY
100% Buy
0% Hold
0% Sell
Target price
$94.67
Est return
26.22%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +0.0 | -9.5 | -8.7 | +4.2 | ||||||||
| 2022 | -9.2 | -10.5 | -4.3 | -13.2 | -18.6 | +27.5 | -2.1 | +20.1 | +7.3 | -15.0 | +31.5 | -12.1 |
| 2023 | +0.1 | -11.4 | -14.4 | -2.0 | +26.2 | -0.6 | +35.0 | -8.8 | -2.2 | -9.8 | +6.8 | +4.3 |
| 2024 | -4.9 | +16.1 | -9.2 | -5.0 | -2.0 | -5.3 | +47.8 | +3.8 | -3.9 | -11.3 | -1.8 | -9.5 |
| 2025 | -1.7 | +7.4 | +3.5 | +23.9 | -1.4 | -0.9 | +11.1 | +4.7 | +13.3 | -4.2 | +13.5 | +0.8 |
| 2026 | +4.5 | -0.4 | +4.7 | +11.7 | -12.5 | +32.0 | +18.2 | +7.1 | -5.3 |



